Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-54781532 (formulation 1)
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JNJ-54781532 (formulation 1) is a specific oral tablet formulation of JNJ-54781532, a selective Janus kinase 1 (JAK1) inhibitor developed by Janssen Research & Development. It was designed for the treatment of chronic inflammatory diseases, most notably rheumatoid arthritis and atopic dermatitis. By inhibiting JAK1, the drug interferes with the JAK-STAT signaling pathway, thereby reducing the production and activity of pro-inflammatory cytokines such as interleukin-6 (IL-6). In clinical development, Formulation 1 (consisting of 30 mg tablets) served as the reference formulation in pharmacokinetic studies comparing the bioavailability of different oral delivery formats, including higher-strength single-tablet versions (Formulation 2).
- Other names
- Formulation 1Formulation1Formulation-1
02
Targets
Beyond the preview
Go deeper on JNJ-54781532 (formulation 1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-54781532 (formulation 1).